• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Conformis Inc.

    9/5/23 6:08:13 AM ET
    $CFMS
    Industrial Specialties
    Health Care
    Get the next $CFMS alert in real time by email
    S-8 POS 1 brhc20058249_s8pos.htm S-8 POS
    As filed with the Securities and Exchange Commission on September 5, 2023
    Registration No. 333-205477
    Registration No. 333-217872
    Registration No. 333-223802
    Registration No. 333-229215
    Registration No. 333-231211
    Registration No. 333-236849
    Registration No. 333-236850
    Registration No. 333-241109
    Registration No. 333-249865
    Registration No. 333-253879
    Registration No. 333-256833
    Registration No. 333-260883
    Registration No. 333-263231
    Registration No. 333-263545
    Registration No. 333-264088
    Registration No. 333-270177


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549


     
    FORM S-8
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-205477
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-217872
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-223802
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-229215
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-231211
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-236849
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-236850
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-241109
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-249865
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-253879
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-256833
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-260883
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-263231
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-263545
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-264088
    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-270177
    UNDER
    THE SECURITIES ACT OF 1933


    Conformis, Inc.
    (Exact name of registrant as specified in its charter)



    Delaware
     
    56-2463152
    (State or other jurisdiction of incorporation or organization)
     
    (I.R.S. Employer Identification No.)
     
    600 Technology Park Drive
    Billerica, MA 01821
    (781) 345-9001
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
     
    restor3d, Inc.
    Attn: Corporate Secretary
    311 W. Corporation St.
    Durham, NC 27701
    (984) 888-0593
    (Name, address, including zip code, and telephone number, including area code, of agent for service)


     
    Copy to:
     
    William J. Zawrotny
    Jones Day
    1221 Peachtree Street N.E., Suite 400
    Atlanta, GA 30361
    (404) 521-3939


    Approximate date of commencement of proposed sale to the public: Not applicable
     
    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.  ☐
     
    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.  ☐
     
    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐
     
    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐
     
    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  ☐
     
    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 431(b) under the Securities Act, check the following box.  ☐
     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☐
    Accelerated filer
    ☐
           
    Non-accelerated filer
    ☒
    Smaller reporting company
    ☒
           
       
    Emerging growth company
    ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐



    DEREGISTRATION OF SECURITIES
     
    This post-effective amendment filed by Conformis, Inc. (the “Company”), deregisters all securities that remain unsold under the following registration statements on Form S-8 (the “Registration Statements”) filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”):
     

    •
    Registration Statement No. 333-205477, registering 7,826,820 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”);
     

    •
    Registration Statement No. 333-217872, registering 1,301,986 shares of Common Stock;
     

    •
    Registration Statement No. 333-223802, registering 1,365,856 shares of Common Stock;
     

    •
    Registration Statement No. 333-229215, registering 1,958,726 shares of Common Stock;
     

    •
    Registration Statement No. 333-231211, registering 3,000,000 shares of Common Stock;
     

    •
    Registration Statement No. 333-236849, registering 2,112,822 shares of Common Stock;
     

    •
    Registration Statement No. 333-236850, registering 378,017 shares of Common Stock;
     

    •
    Registration Statement No. 333-241109, registering 200,000 shares of Common Stock;
     

    •
    Registration Statement No. 333-249865, registering 75,000 shares of Common Stock;
     

    •
    Registration Statement No. 333-253879, registering 2,866,390 shares of Common Stock;
     

    •
    Registration Statement No. 333-256833, registering 6,000,000 shares of Common Stock;
     

    •
    Registration Statement No. 333-260883, registering 150,000 shares of Common Stock;
     

    •
    Registration Statement No. 333-263231, registering 3,000,000 shares of Common Stock;
     

    •
    Registration Statement No. 333-263545, registering 900,000 shares of Common Stock;
     

    •
    Registration Statement No. 333-264088, registering 850,000 shares of Common Stock; and
     

    •
    Registration Statement No. 333-270177, registering 120,000 shares of Common Stock.
     
    On September 5, 2023 (the “Effective Time”), the Company completed the merger contemplated by the Agreement and Plan of Merger (the “Merger Agreement”), dated as of June 22, 2023, with restor3d, Inc. (“restor3d”) and Cona Merger Sub Inc., a wholly owned subsidiary of restor3d (“Merger Sub”). Pursuant to the Merger Agreement, Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of restor3d (the “Merger”). Upon consummation of the Merger, at the Effective Time, each outstanding share of Common Stock of the Company (other than shares owned by the Company, restor3d or Merger Sub (which shares were canceled) and shares with respect to which appraisal rights were property exercised and not withdrawn under Delaware law) was automatically converted into the right to receive $2.27 in cash, without interest. In connection with the completion of the Merger and related transactions contemplated by the Merger Agreement, the offerings pursuant to the above-referenced Registration Statements have been terminated.
     
    In accordance with undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any and all securities that had been registered for issuance but remain unsold at the termination of the offerings, this post-effective amendment removes from registration any and all securities that were registered under the Registration Statements and remain unsold at the termination of the offerings. Each of the Registration Statements is hereby amended, as appropriate, to reflect the deregistration of such securities.


    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, each registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Durham, State of North Carolina, on September 5, 2023.

     
    CONFORMIS, INC.
       
     
    By:
    /s/ J. Kurt Jacobus
     
    Name:
    J. Kurt Jacobus
     
    Title:
    President
     
    Note: No other person is required to sign this Post-Effective Amendment to the Registration Statements on Form S-8 in reliance upon Rule 478 under the Securities Act of 1933.



    Get the next $CFMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CFMS

    DatePrice TargetRatingAnalyst
    11/4/2021$2.50 → $2.00Outperform
    Oppenheimer
    9/22/2021$3.00 → $2.50Outperform
    Oppenheimer
    More analyst ratings

    $CFMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • restor3d Completes Acquisition of Conformis

      DURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis' stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisition, shares of Conformis' common stock ceased trading on the NASDAQ prior to the opening of the NASDAQ on September 5, 2023. "We are extremely excited to complete this important transaction and look forward to leveraging our combined portfolio to deliver personalized orthopedic solutions for the whole human body," said J. Kurt Jacobus, CEO o

      9/5/23 8:18:31 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conformis Stockholders Vote "FOR" the Pending Merger with restor3d

      BILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co., LLC ("Glass Lewis"), have each recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS and Glass Lewis share its be

      8/23/23 8:00:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote "FOR" the Pending Merger with restor3d

      BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), has recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS shares its belief that the proposed merger with restor3d is in the best inte

      8/21/23 4:10:25 PM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer reiterated coverage on Conformis with a new price target

      Oppenheimer reiterated coverage of Conformis with a rating of Outperform and set a new price target of $2.00 from $2.50 previously

      11/4/21 10:00:09 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Oppenheimer reiterated coverage on Conformis with a new price target

      Oppenheimer reiterated coverage of Conformis with a rating of Outperform and set a new price target of $2.50 from $3.00 previously

      9/22/21 7:20:22 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Financials

    Live finance-specific insights

    See more

    $CFMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Conformis Reports First Quarter 2023 Financial Results

      BILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary Total revenue of $12.8 million, a decrease of 17% year-over-year on a reported and constant currency basis.Product revenue of $12.7 million, a decrease of 15% year-over-year on a reported basis and 14% on a constant currency basis.Conformis hip system revenue of $0.8 million, an increase of 3% year-over-year.Cash and cash equivalents of $37.8 million as of March 31, 2023.   Three months ended March 31,

      5/8/23 8:05:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023

      BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephone, please use the information below for dial-in access. Date and Time

      4/13/23 4:30:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results

      BILLERICA, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022 Summary Total revenue of $17.4 million, an increase of 13% year-over-year on a reported basis and 14% on a constant currency basis.Product revenue of $14.2 million, a decrease of 7% year-over-year on a reported basis and 6% on a constant currency basis.Hip system revenue of $0.6 million, a decrease of 15% year-over-year.Cash and cash equivalents of $48.7 million as of December 31, 2022.First procedur

      3/1/23 4:05:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form 4: Fischetti Gary P returned 10,470 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:51 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form 4: Johnston Philip W returned 19,273 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:47 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form 4: Augusti Mark A was granted 17,778 shares and returned 190,277 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:53 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Conformis, Inc. Appoints Michael Fillion as Chief Operating Officer

      BILLERICA, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Michael Fillion has joined the Company as its Chief Operating Officer. "We are pleased to announce the addition of Michael Fillion as Chief Operating Officer. Mike brings to this role 30 years of experience in manufacturing and operations with a strong focus in precision metal products, medical devices, continuous improvement, and strategic business planning," said Mark Augusti, President and Chief Executive officer. "I look forward to the contributions he will make as a member of the Conformis team." Michael Fillion Prior to joining Conformis, Michael served as the Executive Vice Pr

      4/1/22 5:00:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Appoints Denise Pedulla as Chief Legal Officer and Corporate Secretary

      BILLERICA, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Denise Pedulla has joined the Company as its Chief Legal Officer and Corporate Secretary. "We are pleased to announce the addition of Denise Pedulla as Chief Legal Officer and Corporate Secretary. Her strong public company experience and leadership capabilities will help support our growth strategy and further strengthens our executive team," said Mark Augusti, President and Chief Executive Officer. "I look forward to the contributions she will make as a member of the Conformis team." Denise Pedulla Prior to joining Conformis, Denise served as the General Counsel and Corporate Secreta

      3/14/22 4:30:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Appoints James Paiva as its new Vice President of U.S. Marketing; Inducement Grant Reported

      BILLERICA, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed James Paiva as its new Vice President, U.S. Marketing. "Conformis is pleased to welcome James Paiva as the new V.P. of U.S. Marketing. As we continue to advance our growth strategy, we are confident that James' extensive background in new product introductions and multi-channel marketing will help to strengthen Conformis brand recognition and position us to capitalize on anticipated growth in the ambulatory surgery center space," said Mark Augusti, President and Chief Executive Officer.  "I look forward to the contributions James will make as a member of Confo

      11/8/21 9:00:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CFMS
    SEC Filings

    See more
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      7/10/23 5:14:02 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      2/14/23 12:20:12 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      2/13/23 10:56:02 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form 15-12G filed by Conformis Inc.

      15-12G - Conformis Inc (0001305773) (Filer)

      9/15/23 9:56:53 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form S-8 POS filed by Conformis Inc.

      S-8 POS - Conformis Inc (0001305773) (Filer)

      9/5/23 6:08:15 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form S-8 POS filed by Conformis Inc.

      S-8 POS - Conformis Inc (0001305773) (Filer)

      9/5/23 6:08:13 AM ET
      $CFMS
      Industrial Specialties
      Health Care